CLOs on the Move

American Association of Nuerological Surgeons

www.aans.com

 
American Association of Nuerological Surgeons is a Rolling Meadows, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aans.com
  • 5550 5550 Meadowbrook Dr
    Rolling Meadows, IL USA 60008
  • Phone: 847.378.0500

Executives

Name Title Contact Details

Similar Companies

iHealth Analytics

iHealth Analytics LLC is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Nurtur Health, Inc.

Nurtur Health, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Alternative Resources Company

Alternative Resources Company is a Valhalla, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Circle the City

Circle the City is a nonprofit community health organization that provides high quality, holistic healthcare to people experiencing homelessness in Maricopa County.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic